Loading, Please Wait...
Company Demonstrates Reduction of Neuroinflammation Through Administration of Proprietary Noble Gas-Based Therapeutic
SAN DIEGO, CA--(Marketwired - Jan 19, 2016) - Nobilis Therapeutics, a biotechnology company dedicated to clinical development of Noble Gas-based medical interventions, announced today filing of a patent demonstrating inhibition of neuroinflammation using its proprietary product candidate NBTX-001. Experimental in vitro data presented in the patent demonstrates that treatment with NBTX-001 resulted in suppression of inflammatory mediators, as well as blocked maturation of important immunological effector cells termed dendritic cells.
Neuroinflammation is a pathological process in which cells that normally exist to protect the brain become hyperactive, and as a result start damaging healthy brain cells. This process is associated with release of inflammatory mediators which affect behavior and cognitive function.
While neuroinflammation is associated with numerous neurodegenerative conditions, the Company utilized an experimental system specifically applicable to Alzheimer's disease. The experiments demonstrated that when exposed to Alzheimer's associated proteins macrophages produced less inflammatory mediators in the presence of NBTX-001.
This filing adds to Company's existing intellectual property that covers the use of NBTX-001 and related immune modulation in conditions ranging from Post-Traumatic Stress Disorder (PTSD), to Autism, to various psychiatric and neurodegenerative diseases. While the previous patent filing covered modulation of adaptive immune responses, as well as of NBTX-001 induced alteration of cytokine profiles, the current patent filing is focused on manipulation of innate immune cells and its biological activities.
"As a clinician and a drug developer, I see first-hand the devastation brought about by Alzheimer's disease, a condition that, according to the National Institute on Aging affects over 5 million Americans1. The data reported in the current patent application is the first step in our efforts to commercially develop NBTX-001 for this condition," said Dr. Vlad Bogin, founder and CEO of Nobilis Therapeutics. "Modulation of neuroinflammation will be initially applied as a monotherapy, with subsequent plan to combine it with immunological and small molecule interventions. At Nobilis we believe that most chronic neurodegenerative diseases require multimodal targeting of pathological pathways to ensure higher probability of a clinical impact."
"Neuroinflammation plays a central effector role in many aspects of neurodegeneration, whether it is caused by plaque formation, as in the case of Alzheimer's; by immunological attack, as in the case of multiple sclerosis; or chronic inflammation, as in the case of chronic traumatic encephalopathy. We are excited to translate current results from experimental systems into clinic, as we believe that we may have an economic, safe, and scalable approach to a plethora of neurological conditions," said Thomas Ichim, Ph.D, Chief Scientific Officer of Nobilis Therapeutics.
While no cure exists for Alzheimer 's disease, certain treatments are approved for amelioration of its symptoms. Despite the lack of effect at on long term progression, current drugs have sold $4.3 billion in 2013, with expected sales of $13 billion by 20232.
About Nobilis Therapeutics, LLC
Nobilis Therapeutics, LLC is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gas mixtures that have exceptional safety profile proven by decades of clinical use. The Company leverages the experience and expertise of its international team that has successfully used this technology in treatment of over 500 patients for conditions ranging from PTSD to substance abuse.